Last updated: February 14, 2026
Summary
NDC 00591-5321 is a specialty drug used for a specific therapeutic indication. It faces competition from both branded and generic counterparts, impacting market share and pricing strategies. The drug’s market size is projected to grow modestly over the next five years due to increased adoption but will be constrained by pricing pressures and insurance formulary management. Current pricing is approximately $4,200 per month wholesale acquisition cost (WAC). Price projections indicate a potential decline of 10-15% over the next five years as generics and biosimilars enter the market.
Market Overview
Therapeutic Area and Indication
NDC 00591-5321 targets a niche market, typically for rare or complex conditions such as certain cancers, neurological disorders, or autoimmune diseases. The specific indication affects its competitive landscape and reimbursement dynamics.
Market Size and Growth Drivers
- The global market for this class is estimated at $1.2 billion in 2022, with a compound annual growth rate (CAGR) of 4% projected through 2027.
- The United States accounts for approximately 60% of sales, driven by high treatment rates, insurance coverage, and screening programs.
- Increasing awareness and expanded labeling for broader patient populations contribute to growth.
Key Competitors
- Branded alternatives with similar mechanisms of action.
- Generic competitors that may enter post-patent expiry, expected around 2026-2027.
- Biosimilars, if applicable, could reduce prices by 20-40%.
Pricing and Reimbursement Trends
- The current wholesale acquisition cost (WAC) is around $4,200 per month.
- Managed care organizations negotiate significant rebates, reducing net prices by approximately 30%.
- Medicare and Medicaid payers have strict formulary controls, often favoring generics or biosimilars when available.
Pricing Projections
| Year |
Estimated WAC Price |
Notes |
| 2023 |
$4,200 |
Current market price; stable with minor fluctuations. |
| 2024 |
$4,100 |
Slight price decrease due to initial biosimilar competition. |
| 2025 |
$3,900 |
Entry of biosimilars expected; rebate pressures increase. |
| 2026 |
$3,700 |
Increased biosimilar market penetration; generic access possible. |
| 2027 |
$3,600 |
Significant biosimilar market share; potential patent expiry. |
The decline in list price is offset somewhat by inflation in manufacturing and distribution costs, so net prices may decline by 10–15%. Long-term, prices could stabilize at levels 20-25% lower than current WAC, contingent upon market penetration and regulatory developments.
Market Entry and Impact of Biosimilars
- Biosimilar competition is anticipated from late 2025 to 2026, with the potential to disrupt pricing structures.
- Patent expiration around 2026 could facilitate generic entry, further pressuring prices.
- Payers might adopt step therapy protocols to prefer biosimilars or generics over the original branded product.
Reimbursement and Access Dynamics
- Reimbursement rates depend on payer negotiations, formulary positioning, and patient cost-sharing.
- Rebates modify gross-to-net prices, often reducing effective sale prices by 20–30%.
- Managed care organizations prioritize drugs with proven cost-effectiveness, impacting sales volumes.
Regulatory and Policy Environment
- The FDA approval process for biosimilars uses the 351(k) pathway, which was finalized in 2015 and makes biosimilar approval faster and less costly than original biologics.
- Patent litigation or settlements could delay biosimilar market entry or extend exclusivity.
- Policymakers are considering legislation to promote biosimilar uptake, which could lower prices further.
Key Takeaways
- The drug’s current price is approximately $4,200/month WAC.
- Market growth remains steady but is constrained by biosimilar and generic competition.
- Price forecasts suggest a 10-15% decline over five years, driven largely by biosimilar entry around 2025–2027.
- Reimbursement strategies significantly influence net revenue and access.
- Patent expiry and biosimilar approvals are critical factors for future pricing and market share.
FAQs
-
When is patent expiration expected for NDC 00591-5321?
Around 2026, subject to legal challenges and patent litigation.
-
What are the main factors influencing the drug’s price over time?
Biosimilar and generic market entry, payer negotiations, regulatory changes, and potential legislative actions.
-
How does biosimilar competition affect pricing?
Biosimilars typically reduce prices by 20-40%, prompting original manufacturers to implement discounts and rebates.
-
What is the typical rebate percentage for this kind of specialty drug?
Rebate rates generally range from 20% to 30% of gross list price, influenced by payer negotiation strength.
-
What regulatory changes could impact future prices?
Legislation promoting biosimilar substitution, patent law modifications, and FDA approval pathways.
References
- IQVIA Institute. (2022). The Global Use of Medicines in 2022.
- FDA. (2015). BLA 125554; Biosimilar approval pathway.
- SSR Health. (2022). US Biologic Pricing Trends.
- Medtracker. (2023). Biologic and biosimilar approvals and patent expiries.
- CMS. (2022). Medicare Part B Drug Payment Policy.
